GS
VIVO

Gagnon Securities’s Meridian Bioscience Inc VIVO Stock Holding History

Gagnon Securities’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-44,361
Closed -$854K – 113
2021
Q3 		$854K Buy
+44,361
New +$884K 0.13% 62

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Gagnon Securities's VIVO Position: Q4 2021 in Review

Gagnon Securities sold out of Meridian Bioscience Inc (VIVO) in Q4 2021, closing a stake of 44,361 shares — an estimated $854K sold.

Gagnon Securities first reported a position in VIVO in Q3 2021 and held it in 1 quarter. The position peaked at $854K in Q3 2021. 180 funds tracked by Wall St. Rank hold VIVO as of Q4 2021.

  • Gagnon Securities reported no remaining Meridian Bioscience Inc position as of Q4 2021 after selling out during the quarter.
  • Gagnon Securities sold 44,361 Meridian Bioscience Inc shares in Q4 2021, an estimated $854K.
  • Gagnon Securities first reported a position in Meridian Bioscience Inc in Q3 2021 and held it in 1 quarter.
  • Gagnon Securities's Meridian Bioscience Inc position peaked at $854K in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2021.

Based on Gagnon Securities's 13F filing for Q4 2021, filed 8 Feb 2022.